Clinical Trial

A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan

Study acronym: REACT-HFrEF-RO
Completed
View on ClinicalTrials.gov →
Summary
The aim of this study was to describe the real-world clinical profile, treatment patterns, and guideline alignment of patients with heart failure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan in routine clinical practice in Romania. The study used secondary use of data, with all analyses conducted on anonymized, pre-existing data collected for routine clinical and administrative purposes.
Protocol Amendment History 2 changes
critical Trial completed 2026-07-07
notable Enrollment increased: 500 -> 2508 participants 2026-07-07
Trial Details
NCT Number NCT07465679
Lead Sponsor Novartis Pharmaceuticals
Conditions Heart Failure With Reduced Ejection Fraction
Enrollment 2,508 participants
Start Date 2026-01-28
Primary Completion 2026-03-10 (estimated)
Study Completion 2026-03-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-06